Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Clinical evidence

XOMA 358 First-in-Human study

19 evidence topics · 7 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using safety and tolerability as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary
  • The study enrolled only healthy adult males and gave single doses, so it describes pharmacokinetics, pharmacodynamics, and short-term tolerability without information on repeated dosing or on patients with hyperinsulinism.
  • Only the abstract and company releases are openly available; the full text, with eligibility, disposition, baseline characteristics, and adverse event tables, is closed access, and no registry identifier was found. The reported number of healthy volunteers differs across documents (29 in the publication; 22 across two phase 1 studies in a later publication).